Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial

Background: Dalfampridine extended-release (ER) tablets, 10 mg twice daily, have been shown to improve walking in people with multiple sclerosis. We evaluated the safety and efficacy of dalfampridine-ER 5 mg compared with 10 mg. Methods: Patients were randomized to double-blind treatment with twice-...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Int J MS Care
Hoofdauteurs: Yapundich, Robert, Applebee, Angela, Bethoux, Francois, Goldman, Myla D., Hutton, George J., Mass, Michele, Pardo, Gabriel, Klingler, Michael, Henney, Herbert R., Blight, Andrew R., Carrazana, Enrique J.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: The Consortium of Multiple Sclerosis Centers 2015
Onderwerpen:
Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4455866/
https://ncbi.nlm.nih.gov/pubmed/26052259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7224/1537-2073.2014-040
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items